Supriya Lifescience sees 20% revenue growth, targets ₹1,000 crore by FY '27

Supriya Lifescience Limited reported a 20% year-on-year revenue growth for Q2 FY '26, reaching ₹200 crores, and a 38% sequential increase. EBITDA for the quarter stood at ₹73 crores, up 12% year-on-year, with an EBITDA margin of 36%. For H1 FY '26, revenue was ₹345 crores, a 6% year-on-year growth, and PAT stood at ₹85 crores, with a PAT margin of 25%. The company reiterated its guidance for approximately 20% annual revenue growth and EBITDA margins in the 33%-35% range, expecting a stronger second half of FY '26.

Exports remain a cornerstone, contributing 81% to Q2 FY '26 revenues, with backward integration accounting for 79% of revenues. The Ambernath facility is progressing, with validation campaigns underway and commercial contributions expected from Q4 FY '26, focusing initially on liquid anesthetics and oral solids. The company also anticipates reaching ₹1,000 crore revenue by Financial Year '27, supported by a healthy product pipeline and 3-4 planned launches this year across key therapeutic areas.

CAPEX for Q2 FY '26 was ₹28 crores, with H1 FY '26 CAPEX totaling ₹42 crores, primarily directed towards the Ambernath facility. An additional CAPEX of around ₹80 crores is expected for the remainder of FY '26 for maintenance and small projects like the Ribo Block. The DSM project, particularly its food application, is contributing ₹25-30 crores in revenue this year, with full potential of ₹60 crores expected next year upon pharma qualification.